Introduction {#S0001}
============

Metabolic syndrome (MetS) has been linked to accelerated central arterial aging (i.e., increased arterial stiffness and thickness) ([@CIT0001; @CIT0002]). Some prospective studies show that the progression of arterial stiffness was associated with the changes in MetS risk and was significantly more pronounced in MetS subjects ([@CIT0003; @CIT0004]). A growing body of literature suggests that diverse inflammatory and oxidative stress markers correlate with arterial damage ([@CIT0001; @CIT0005; @CIT0006; @CIT0007]) and, thus, with increased arterial stiffness and thickness ([@CIT0008; @CIT0009; @CIT0010; @CIT0011]). Inflammatory markers have been reported to be elevated in patients with diabetes mellitus ([@CIT0012]), and a proinflammatory state accompanies the presence of altered MetS components. MetS treatment and management programs conventionally focus on patients with the condition; however, careful observation for changes in inflammatory and oxidative stress markers and arterial stiffness is also important for patients at risk for developing MetS.

Therefore, our follow-up study included apparently healthy subjects who do not meet the MetS criteria at baseline, and then after 3 years, subdivided the subjects into non-MetS and MetS, and this study included inflammatory and oxidative stress markers and brachial-ankle pulse wave velocity (ba-PWV) together with metabolic risk factors, and investigated the association of these parameters.

Methods and Materials {#S0002}
=====================

Study Participants {#S2001}
------------------

A total of 288 participants between the ages of 30 and 69 years who visited a health promotion center of the National Health Insurance Corporation of Ilsan Hospital in Korea between October 2006 and October 2007 were enrolled in this study. Participants also completed a personal health and medical history questionnaire, which served as a screening tool. The Institutional Review Board of the National Health Insurance Corporation of Ilsan Hospital approved the study protocol, which was conducted in accordance with the Helsinki Declaration. At the end of the 3-year study, participants were subdivided into groups according to the criteria for MetS (non-MetS and MetS).

MetS was diagnosed if the participants showed at least three of the following components: central obesity (i.e., waist circumference \[WC\] \>90 cm for males and \>80 cm for females); high blood pressure (BP) (i.e., systolic BP \[SBP\] ≥130 mm Hg or diastolic BP \[DBP\] ≥85 mm Hg); hyperglycemia (i.e., fasting glucose ≥100 mg/dL); hypertriglyceridemia (i.e., fasting triglycerides \[TGs\] ≥150 mg/dL); and low high-density lipoprotein (HDL)-cholesterol (i.e., HDL-cholesterol \<40 mg/dL for males and \<50 for females) ([@CIT0013; @CIT0014]).

Anthropometric Parameters, Blood Pressure, Blood Collection, and Energy Intake {#S2002}
------------------------------------------------------------------------------

Body mass index (BMI) was calculated as body weight in kilograms divided by the square of the height in meters (kg/m^2^). Waist circumference was measured at the umbilicus with the subjects standing after normal expiration. The SBP and DBP were obtained from the left arms of seated patients with an automatic BP monitor (TM-2654; A&D, Tokyo, Japan) after 20 minutes of rest. After overnight fasting, venous blood samples were collected in ethylenediaminetetraacetic acid-treated or plain tubes, separated into plasma and serum, and then stored at −70°C until analysis. Participants were interviewed about their smoking and drinking behaviors. Dietary intake was assessed using a semiquantitative food frequency questionnaire and a 24-hour recall method. Nutrient intake was determined and calculated based on the 3-day food records using the computer-aided nutritional analysis program (CAN-pro 2.0; Korean Nutrition Society, Seoul, Korea). Total energy expenditure (TEE) (kcal/d) was calculated based on the activity patterns of the study participants, such as basal metabolic rate, 24-hour physical activity, and specific dynamic actions of food.

Measurement of Serum Lipid Profiles and Fasting Glucose, Insulin, and Homeostasis and Model Assessment of Insulin Resistance and Free Fatty Acid {#S2003}
------------------------------------------------------------------------------------------------------------------------------------------------

Fasting total-cholesterol and TG levels were measured using commercially available kits and a Hitachi 7150 autoanalyzer (Hitachi Ltd., Tokyo, Japan). After precipitation of serum chylomicrons using dextran sulfate magnesium, HDL-cholesterol concentrations in the supernatants were enzymatically measured. For participants with serum TG levels \<400 mg/dL, low-density lipoprotein (LDL)-cholesterol levels were estimated directly using the Friedewald formula: LDL-cholesterol = total-cholesterol − (HDL-cholesterol + \[TG/5\]). Fasting glucose levels were measured by the glucose oxidase method using a Beckman glucose analyzer (Beckman Instruments, Irvine, CA, USA). Insulin levels were measured by a radioimmunoassay using a commercial kit (Immuno Nucleo Corporation, Stillwater, MN, USA). Insulin resistance (IR) was calculated based on the homeostasis model assessment (HOMA) using the following equation: HOMA-IR = (fasting insulin \[μIU/mL\] × fasting glucose \[mmol/L\])/22.5. Free fatty acids (FFA) were analyzed with a Hitachi 7150 autoanalyzer.

Measurement of Serum Interleukin-6, Tumor Necrosis Factor-α, High-Sensitivity C-Reactive Protein Levels, and White Blood Cell Counts {#S2004}
------------------------------------------------------------------------------------------------------------------------------------

Serum interleukin (IL)-6 and tumor necrosis factor (TNF)-α concentrations were measured using Bio-Plex™ reagent kits and a Bio-Plexz™ system (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. High-sensitivity C-reactive protein (hs-CRP) levels were measured on an Express Plus™ autoanalyzer (Chiron Diagnostics Co., Walpole, MA, USA) using commercially available hs-CRP-Latex (II) X2 kits (Seiken Laboratories Ltd., Tokyo, Japan). White blood cell (WBC) counts were determined using a hematology analyzer from HORIBA ABX Diagnostic (HORIBA ABX SAS, Parc Euromedicine, France).

Plasma Oxidized-LDL, Malondialdehyde, and ba-PWV Measurements {#S2005}
-------------------------------------------------------------

Plasma oxidized (ox)-LDL levels were measured using an enzyme immunoassay (Mercodia, Uppsala, Sweden). The absorbances of the resulting color reactions were measured at a wavelength of 450 nm using a Wallac Victor^2^ multilabel counter (Perkin Elmer Life Sciences, Turku, Finland). The wavelength correction was set to 540 nm. Plasma malondialdehyde (MDA) concentrations were measured based on the production of thiobarbituric acid-reactive substances (TBARS Assay Kit, Zepto-Metrix Co., Buffalo, NY, USA). Branchial--ankle pulse wave velocities were measured using an automatic waveform analyzer (model VP-1000; Nippon Colin Ltd., Komaki, Japan).

Data Analysis {#S2006}
-------------

Statistical analyses were performed using SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL, USA). The skewed variables were logarithmically transformed for statistical analysis. For descriptive purposes, mean values were presented using untransformed values. Results are expressed as means ± standard error. A two-tailed *P* value of \<.05 was considered statistically significant. Frequency was tested with the chi-square test. Paired *t* tests were used to evaluate differences between baseline and 3-year follow-up levels. Differences in the clinical variables between the without MetS and with MetS outcome groups were tested by independent *t* tests. A general linear model test was applied to adjust for baseline values. Pearson's correlation coefficients were used to examine the relationships between variables. Multiple logistic regression analyses were also performed.

Results {#S0003}
=======

Clinical Characteristics, Metabolic Risk Factors, Inflammatory and Oxidative Stress Markers, ba-PWV, and Nutrient Intake at Baseline and 3-Year Follow-Up {#S2007}
---------------------------------------------------------------------------------------------------------------------------------------------------------

After 3 years, participants showed a decrease in HDL-cholesterol (*P* \< .001), insulin (*P* = .039), and FFA (*P* \< .001), and an increase in WC (*P* \< .001), DBP (*P* = .001), total-cholesterol (*P* = .002), LDL-cholesterol (*P* \< .001), serum TNF-α (*P* = .033), MDA (*P* \< .001), ox-LDL (*P* \< .001), and ba-PWV (*P* \< .001) ([Table 1](#T1){ref-type="table"}). The estimated total calorie intake was reported at baseline (2439 ± 19 kcal/d) and at the 3-year follow-up (2428 ± 18 kcal/d). No significant differences in macronutrient intake, TEE, smoking, or drinking between the baseline and the 3-year follow-up were noted in whole subjects (data not shown). Additionally, we observed significant decreases in TEE, and significant increases in total calorie intake (TCI)/TEE in the MetS outcome groups, which were not observed in the non-MetS outcome groups (data not shown).

Metabolic Risk Factors and Lipid Profiles According to MetS Outcome at 3 Years {#S2008}
------------------------------------------------------------------------------

Within a 3-year interval, 15.6% (45 out of 288) of the participants met the criteria for MetS. At the 3-year follow-up, participants were divided into two groups according to MetS outcome: those who developed MetS (*n* = 45) and those who did not develop MetS (*n* = 243). At baseline, participants who later developed MetS showed significantly unfavorable measurements for baseline BMI, WC, BP, TG, HDL-cholesterol, glucose, insulin, and HOMA-IR index ([Table 2](#T2){ref-type="table"}). After 3 years, participants who did not develop MetS showed a significant increase in WC, DBP, total- and LDL-cholesterol, and a significant decrease in HDL-cholesterol and FFA. Participants who developed MetS showed a significant increase in BMI, WC, BP, TG, and glucose, and a significant decrease in HDL-cholesterol. Changes in BMI, WC, BP, TG, HDL-cholesterol, glucose, HOMA-IR index, and FFA were significantly different between the non-MetS and MetS groups after adjustment for baseline values. At the 3-year follow-up, participants who developed MetS had significantly unfavorable measurements for BMI, WC, BP, TG, HDL-cholesterol, glucose, insulin, HOMA-IR index, and FFA ([Table 2](#T2){ref-type="table"}).

###### 

Clinical characteristics, metabolic risk factors, inflammatory and oxidative stress markers, and ba-PWV at baseline and after 3 years

                                                                                          Non-MetS (*n* = 288)                   
  --------------------------------------------------------------------------------------- ---------------------- --------------- --------
  Age (y)                                                                                 46.0 ± 0.56            49.0 ± 0.57     \<.001
  BMI (kg/m^2^)                                                                           23.1 ± 0.15            23.2 ± 0.15     .081
  Waist (cm)                                                                              81.9 ± 0.40            85.2 ± 0.42     \<.001
  SBP (mm Hg)                                                                             117.0 ± 0.80           118.3 ± 0.85    .084
  DBP (mm Hg)                                                                             71.6 ± 0.62            73.6 ± 0.66     .001
  TGs (mg/dL)[^a^](#TFN1001){ref-type="table-fn"}                                         100.3 ± 3.39           104.6 ± 3.82    .347
  Total-cholesterol (mg/dL)[^a^](#TFN1001){ref-type="table-fn"}                           188.3 ± 1.93           193.4 ± 1.91    .002
  HDL-cholesterol (mg/dL)[^a^](#TFN1001){ref-type="table-fn"}                             55.3 ± 0.87            51.9 ± 0.84     \<.001
  LDL-cholesterol (mg/dL)[^a^](#TFN1001){ref-type="table-fn"}                             113.3 ± 1.85           121.2 ± 1.71    \<.001
  Glucose (mg/dL)[^a^](#TFN1001){ref-type="table-fn"}                                     90.6 ± 0.59            92.3 ± 0.56     .006
  Insulin (IU/mL)[^a^](#TFN1001){ref-type="table-fn"}                                     8.40 ± 0.20            8.05 ± 0.23     .039
  [^b^](#TFN1002){ref-type="table-fn"}HOMA-IR[^a^](#TFN1001){ref-type="table-fn"}         1.89 ± 0.05            1.85 ± 0.06     .196
  FFA (Eq/L)[^a^](#TFN1001){ref-type="table-fn"}                                          513.5 ± 14.5           437.2 ± 12.3    \<.001
  hs-CRP (mg/dL)[^a^](#TFN1001){ref-type="table-fn"}                                      1.17 ± 0.14            1.12 ± 0.13     .943
  Serum IL-6 (pg/mL)[^a^](#TFN1001){ref-type="table-fn"}                                  3.59 ± 0.19            3.34 ± 0.14     .964
  Serum TNF-α (pg/mL)[^a^](#TFN1001){ref-type="table-fn"}                                 8.75 ± 0.48            9.36 ± 0.48     .033
  WBCs (×10^9^/L)[^a^](#TFN1001){ref-type="table-fn"}                                     5.45 ± 0.10            5.35 ± 0.09     .538
  [^c^](#TFN1003){ref-type="table-fn"}ba-PWV (cm/s)[^a^](#TFN1001){ref-type="table-fn"}   1293.6 ± 10.9          1334.2 ± 11.4   \<.001
  MDA (nmol/mL)[^a^](#TFN1001){ref-type="table-fn"}                                       9.75 ± 0.16            11.1 ± 0.16     \<.001
  ox-LDL (U/L)[^a^](#TFN1001){ref-type="table-fn"}                                        33.2 ± 0.67            44.1 ± 0.66     \<.001

^a^Means ± SE tested by logarithmic transformation, *P* values derived from paired *t* test.

^b^HOMA-IR = (fasting insulin (μIU/mL) × fasting glucose (mmol/L))/22.5.

^c^ba-PWV = brachial--ankle pulse wave velocity.

Abbreviations: BMI -- body mass index; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; TGs -- triglycerides; FFA -- free fatty acids; WBCs -- white blood cells; MDA -- malondialdehyde ; ox-LDL -- oxidized-LDL.

###### 

Clinical characteristics, metabolic risk factors, and lipid profiles according to the MetS outcome at 3 years

                                                  Baseline: non-MetS (*n* = 288)                                                    
  ----------------------------------------------- -------------------------------- -------- --------------------- -------- -------- --------
  Male/female, *n* (%)                            130 (53.5)/113 (46.5)                     30 (66.7)/15 (33.3)            .102     
  Cigarette smoker, *n* (%)                       61 (25.1)                                 16 (35.6)                      .146     
  Alcohol drinker, *n* (%)                        166 (68.3)                                31 (68.9)                      .939     
  BMI (kg/m^2^)                                                                                                                     
  Baseline                                        22.8 ± 0.16                      .521     24.7 ± 0.35           .006     \<.001   
  Follow-up                                       22.8 ± 0.16                               25.2 ± 0.32                    \<.001   
  Change                                          0.05 ± 0.07                               0.49 ± 0.17                    .013     \<.001
  WC (cm)                                                                                                                           
  Baseline                                        81.1 ± 0.42                      \<.001   85.9 ± 0.99           \<.001   \<.001   
  Follow-up                                       84.1 ± 0.44                               91.4 ± 0.81                    \<.001   
  Change                                          2.96 ± 0.37                               5.54 ± 0.80                    .006     \<.001
  SBP (mm Hg)                                                                                                                       
  Baseline                                        115.8 ± 0.86                     .942     123.4 ± 1.94          .001     \<.001   
  Follow-up                                       115.8 ± 0.83                              131.7 ± 2.13                   \<.001   
  Change                                          0.06 ± 0.79                                8.27 ± 2.27                   \<.001   \<.001
  DBP (mm Hg)                                                                                                                       
  Baseline                                        70.5 ± 0.67                      .036     77.4 ± 1.44           \<.001   \<.001   
  Follow-up                                       71.9 ± 0.69                               82.8 ± 1.43                    \<.001   
  Change                                          1.37 ± 0.65                               5.42 ± 1.36                    .013     \<.001
  TGs (mg/dL)                                                                                                                       
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    93.0 ± 3.10                      .589     140.2 ± 12.4          \<.001   \<.001   
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   91.9 ± 3.37                               173.1 ± 12.0                   \<.001   
  Change                                          −1.05 ± 3.03                              32.9 ± 9.25                    .001     \<.001
  Total-cholesterol (mg/dL)                                                                                                         
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    187.5 ± 2.04                     .001     192.6 ± 5.66          .668     .446     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   193.3 ± 2.06                              194.0 ± 5.04                   .926     
  Change                                          5.81 ± 1.76                               1.42 ± 5.10                    .345     .500
  HDL-cholesterol (mg/dL)                                                                                                           
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    56.5 ± 0.96                      .002     48.6 ± 1.67           \<.001   .001     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   53.8 ± 0.92                               41.5 ± 1.26                    \<.001   
  Change                                          −2.70 ± 0.84                              −7.13 ± 1.40                   .008     \<.001
  LDL-cholesterol (mg/dL)                                                                                                           
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    112.4 ± 1.90                     \<.001   118.2 ± 5.98          .368     .688     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   121.4 ± 1.84                              120.0 ± 4.63                   .752     
  Change                                          8.91 ± 1.77                               1.87 ± 5.36                    .141     .157
  Glucose (mg/dL)                                                                                                                   
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    90.0 ± 0.62                      .093     93.5 ± 1.73           .001     .041     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   91.1 ± 0.57                               98.4 ± 1.52                    \<.001   
  Change                                          1.12 ± 0.66                               4.84 ± 1.31                    .023     \<.001
  Insulin (IU/mL)                                                                                                                   
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    8.15 ± 0.21                      .055     9.74 ± 0.59           .443     .008     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   7.78 ± 0.23                               9.52 ± 0.70                    .006     
  Change                                          −0.37 ± 0.26                              −0.22 ± 0.59                   .819     .093
  HOMA-IR                                                                                                                           
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    1.81 ± 0.05                      .160     2.28 ± 0.17           .870     .002     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   1.76 ± 0.06                               2.32 ± 0.19                    \<.001   
  Change                                          −0.05 ± 0.06                              0.04 ± 0.15                    .587     .032
  FFA (Eq/L)                                                                                                                        
  Baseline[^a^](#TFN2001){ref-type="table-fn"}    520.8 ± 16.2                     \<.001   466.9 ± 25.8          .238     .431     
  Follow-up[^a^](#TFN2001){ref-type="table-fn"}   427.4 ± 13.5                              500.0 ± 27.2                   .001     
  Change                                          −93.5 ± 18.6                              33.1 ± 25.6                    \<.001   .004

^a^Means ± SE tested by logarithmic transformation.

^b^ *P* values derived from paired *t* test.

^c^ *P* values derived from independent *t* test.

^d^ *P* values derived after adjustment for baseline value.

Abbreviations: BMI -- body mass index; WC -- waist circumference; SBP -- systolic blood pressure; DBP -- diastolic blood pressure; TGs -- triglycerides; FFA -- free fatty acids.

###### 

Inflammatory and oxidative stress markers and ba-PWV according to MetS outcome at 3 years

                                                  Baseline: non-MetS (*n* = 288)                                              
  ----------------------------------------------- -------------------------------- -------- --------------- -------- -------- --------
  hs-CRP (mg/dL)                                                                                                              
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    1.23 ± 0.16                      .733      0.87 ± 0.08    .442     .153     
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   1.06 ± 0.14                                1.44 ± 0.35             .061     
  Change                                          −0.16 ± 0.21                               0.57 ± 0.36             .147     .022
  Serum IL-6 (pg/mL)                                                                                                          
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    3.66 ± 0.22                      .270      3.24 ± 0.33    .011     .483     
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   3.14 ± 0.14                                4.35 ± 0.47             .002     
  Change                                          −0.53 ± 0.26                               1.11 ± 0.49             .009     .004
  Serum TNF-α (pg/mL)                                                                                                         
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    8.94 ± 0.55                      .147      7.77 ± 0.77    .017     .743     
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   9.33 ± 0.56                                9.49 ± 0.64             .196     
  Change                                          0.40 ± 0.75                                1.73 ± 1.01             .451     .493
  WBCs (×10^9^/L)                                                                                                             
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    5.41 ± 0.11                      .143      5.67 ± 0.22    .137     .235     
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   5.21 ± 0.09                                6.13 ± 0.27             \<.001   
  Change                                          −0.20 ± 0.11                               0.46 ± 0.33             .027     \<.001
  MDA (nmol/mL)                                                                                                               
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    9.69 ± 0.18                      \<.001    10.1 ± 0.39    \<.001   .327     
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   10.9 ± 0.18                                12.2 ± 0.41             .004     
  Change                                          1.21 ± 0.15                                2.15 ± 0.41             .018     .002
  ox-LDL (U/L)                                                                                                                
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    33.3 ± 0.76                      \<.001    32.7 ± 1.34    \<.001   .910     
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   43.6 ± 0.67                                46.9 ± 2.04             .249     
  Change                                          10.2 ± 0.70                                14.3 ± 1.97             .061     .015
  ba-PWV (cm/s)                                                                                                               
  Baseline[^a^](#TFN3001){ref-type="table-fn"}    1274.0 ± 11.1                    \<.001   1396.7 ± 31.8   \<.001   \<.001   
  Follow-up[^a^](#TFN3001){ref-type="table-fn"}   1308.4 ± 11.6                             1469.1 ± 29.3            \<.001   
  Change                                          34.5 ± 7.35                                72.4 ± 19.7             .046     .001

^a^Mean ± SE tested by logarithmic transformation.

^b^ *P* values derived from paired *t* test.

^c^ *P* values derived from independent *t* test.

^d^ *P* values derived after adjustment for baseline value.

Abbreviations: hs-CRP -- high-sensitivity C-reactive protein; IL-6 -- interleukin-6; TNF-α -- tumor necrosis factor-α; WBCs -- white blood cells; MDA -- malondialdehyde ; ox-LDL -- oxidized-LDL; ba-PWV -- branchial--ankle pulse wave velocity.

Inflammatory and Oxidative Stress Markers and ba-PWV According to MetS Outcome at 3 Years {#S2009}
-----------------------------------------------------------------------------------------

At baseline, participants who later developed MetS had significantly higher ba-PWV than those who did not develop MetS (*P* \< .001) ([Table 3](#T3){ref-type="table"}). However, there were no significant differences in inflammatory and oxidative stress markers between the non-MetS and MetS groups at baseline. After 3 years, participants without MetS showed a significant increase in MDA (*P* \< .001), ox-LDL (*P* \< .001), and ba-PWV (*P* \< .001). Participants with MetS showed a significant increase in IL-6 (*P* = .011), TNF-α (*P* = .017), MDA (*P* \< .001), ox-LDL (*P* \< .001), and ba-PWV (*P* \< .001). Changes in hs-CRP (*P* = .022), IL-6 (*P* = .004), leukocyte count (*P* \< .001), MDA (*P* = .002), ox-LDL (*P* = .015), and ba-PWV (*P* = .001) were significantly different between the non-MetS and MetS groups after adjustment for baseline values. Additionally, changes in ba-PWV were significantly different between the two groups after further adjustment for baseline ba-PWV, SBP, DBP, and heart rate (*P* = .002). At the 3-year follow-up, participants with MetS had significantly unfavorable inflammatory and oxidative stress measurements for IL-6 (*P* = .002), leukocyte count (*P* \< .001), MDA (*P* = .004), and ba-PWV (*P* \< .001).

Relationship between Changes in ba-PWV and Changes in Metabolic, Inflammatory, and Oxidative Stress Markers {#S2010}
-----------------------------------------------------------------------------------------------------------

Changes in ba-PWV were positively correlated with changes in SBP (*r* = 0.287, *P* \< .001), DBP (*r* = 0.155, *P* = .010), total-cholesterol (*r* = 0.137, *P* = .024), glucose (*r* = 0.152, *P* = .012), leukocyte count (*r* = 0.121, *P* = .046), and MDA (*r* = 0.131, *P* = .046). Changes in leukocyte count were positively correlated with changes in BMI (*r* = 0.159, *P* = .007), WC (*r* = 0.135, *P* = .023), CRP (*r* = 0.299, *P* \< .001), and IL-6 (*r* = 0.314, *P* \< .001). Changes in MDA were positively correlated with changes in ox-LDL (*r* = 0.139, *P* = .039), DBP (*r* = 0.137, *P* = .033), and total-cholesterol (*r* = 0.176, *P* = .006). Furthermore, changes in IL-6 were positively correlated with changes in CRP (*r* = 0.388, *P* \< .001).

Discussion {#S0004}
==========

Major strengths of this report include the longitudinal, observational study of middle-aged individuals not meeting the MetS criteria, the inclusion of ba-PWV (a marker of arterial stiffness) ([@CIT0015]), and the inclusion of several inflammatory and oxidative stress markers and MetS components. The results of this study suggested that age-associated changes in ba-PWV and inflammatory and oxidative stress markers differ between individuals with and without MetS outcomes. Additionally, the age-related increase in ba-PWV was associated with changes in inflammatory and oxidative stress markers. The age-related increase in arterial stiffness was greater in patients who developed MetS and showed higher levels of inflammatory and oxidative stress markers.

Pulse wave velocity is an established index of arterial stiffness ([@CIT0016]), and ba-PWV shows characteristics similar to those of central aortic PWV ([@CIT0017]). Arterial stiffness, one of the most significant manifestations of vascular aging ([@CIT0018; @CIT0019]), can increase SBP ([@CIT0020; @CIT0021]), and increases with age, even in healthy individuals without clinical cardiovascular disease (CVD) ([@CIT0022]). The underlying mechanisms responsible for arterial stiffness remain unknown; however, oxidative stress, such as the age-related increase in ox-LDL and MDA in middle-aged subjects, could play an important role given that there were positive correlations between changes in ba-PWV and MDA and between MDA and ox-LDL. In our study, multiple logistic regression analysis revealed that change of ba-PWV increased by 0.135 cm/s (95% CI: 0.058, 11.588, *P* = .04) per unit change of MDA levels after adjustment for age and change of BMI, SBP, DBP, total-cholesterol, glucose, and WBCs. Tso et al. ([@CIT0023]) also reported that age and SBP of studied patients were independently associated with ba-PWV. Recently, Brinkley et al. ([@CIT0011]) also suggested that oxidative stress, including ox-LDL, may be related to the pathogenesis of arterial stiffness, independent of other CVD risk factors.

The presence of CVD risk factors, including obesity, has been shown to accelerate the vascular changes that result in arterial stiffening ([@CIT0022]). In this study, age-related changes in BMI, ba-PWV, and inflammatory and oxidative stress markers were greater in individuals who developed MetS than in those who did not. Increased evidence suggests that obesity and being overweight constitute low-grade inflammatory states ([@CIT0024; @CIT0025]). A chronic inflammatory response might increase the blood concentration of acute-phase reactants, including leukocytes ([@CIT0025]). Thus, detecting a high leukocyte count or a change in the count has been linked to predicting specific diseases, such as MetS ([@CIT0026]), subclinical atherosclerosis ([@CIT0025]), and CVD ([@CIT0027]), as well as all-cause mortality ([@CIT0028]). Meanwhile, cytokines, such as IL-6 (a potent leukocyte differentiation factor), have been associated with IR ([@CIT0029]). Interlukin-6, which is produced by immune cells and adipose tissue ([@CIT0030]), increases hepatic synthesis of CRP ([@CIT0031]). In this study, changes in IL-6 were associated with changes in leukocyte count and hs-CRP. In addition, changes in leukocyte count were positively correlated with changes in BMI and ba-PWV. This result supports the previous suggestion of a possible synergistic effect between MetS and inflammation on the arterial wall ([@CIT0001]).

Within 3 years, a considerable number (15.6%; 45 out of 288) of the middle-aged participants of this study fulfilled the criteria for MetS. The incidence of MetS in our middle-aged study population was as high as reported in a survey for Korean middle-aged adults (2005 Korea National Health and Nutrition Examination Survey Report III). Participants with MetS outcomes had significantly unfavorable initial measurements, including baseline BMI, WC, BP, TG, HDL-cholesterol, glucose, insulin, HOMA-IR index, and ba-PWV. These results are consistent with a previous finding of a significant correlation between the baseline MetS component count and MetS development ([@CIT0014]). In fact, Lin et al. ([@CIT0014]) showed that middle-aged adults having one or two MetS components had a 2.8-fold and 7.3-fold increased risk for developing MetS within 5 years, respectively, versus adults having no MetS components.

Additionally in our study, significant decreases in TEE and significant increases in TCI/TEE were observed in the MetS outcome groups after the 3-year follow-up, but which were not observed in the non-MetS outcome groups. Our result is partly in accordance with the work of Esmaillzadeh and Azadbakht ([@CIT0032]), which shows that higher dietary energy density was significantly associated with a greater risk of MetS and most of its components. It may suggest that usual lifestyle is closely associated with the risk of MetS and important in the prevention of MetS.

In conclusion, this study showed that the simultaneous occurrence of MetS and higher proinflammatory and oxidative stress markers increase the likelihood for greater age-related increases in arterial stiffness. Therefore, lifestyle modifications, such as caloric restriction and exercise, are recommended to the middle-aged individuals at risk for MetS criteria as an efficacious therapeutic intervention for preventing MetS and the progression of arterial stiffness.
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